This morning I watched Steph Curry hit 286 straight three-pointers in a matter of minutes. The video, which stitched together the Golden State point guard’s storied 2014-15 MVP season, was on YouTube, naturally. I watched it multiple times, which I imagine is a phenomenon that accounts for a number of its more than 2.4 million views to date. But the most instructive screening came with the sound off—when I couldn’t hear “Curry! Three!” and “Curry hits the Three” and “Curry with the deep three” and “Curry unloads the three” and some version of that 282 more times.
Watching Curry—who, in the following season would outdo even this one, hitting an unimaginable 402 threes and winning the only unanimous MVP title in NBA history—is like sneaking into a master class in shooting. There he is, again and again, poised with the perfect footing, the perfect form, the perfect flick of the wrist, the perfect follow-through. There he is, in a seemingly effortless sequence of motions, sinking 25-footers in high, rounded, tractor-beam arcs that slip silently through the rim.
How anyone can aim like that—with such precision and consistency—is a great human mystery. And indeed, no matter what neuroscientists may claim, we’re not close to solving it. Some speak of the “Quiet Eye,” discovered by Canadian researcher Joan Vickers, which is a relatively long-lasting period of fixed gaze that many athletes seem to have just prior to aiming. (The quiet eye appears to tame the raucous brain that can’t seem to stay still.) Others point to a “mosaic of well-known cortical and subcortical areas associated with the planning and execution of goal-directed movements.” Others suggest aiming is an unseen tête-à-tête between lightning-fast “allocentric” (focusing on something or someone outside of yourself) assessments and “egocentric” ones, between framing the target in space and framing one’s own position relative to it—which involves activity across multiple regions of the brain, from the early visual cortex (allocentric judgment) to the parietofrontal cortex (egocentric), from the superior occipital gyrus (natch) to the inferior occipital gyrus, and then some.
More from FORTUNE
In short, still much to figure out. But that said, there is something that improves almost everyone’s aim—and that’s to give us a target that we instinctively want to hit. This is why putting a decal sticker of a fly near the drain on a men’s room urinal (or actually painting it into the porcelain receptacle)—a practice that is becoming more common in places like airports—is so extraordinarily effective at reducing what its politely referred to as “human spillage.” When the motionless fly targets came to urinals at Amsterdam’s Schiphol Airport, spillage rates reportedly dropped by 80% and led to a significant reduction in bathroom cleaning costs, to say nothing of wet shoes.
This is the quiet power of such target priming—a costless incentive to take a moment and aim. Very few, if any, of us will ever be able to square up and hit a three-pointer like Steph Curry. But there is magic nonetheless in the simple things we can do to improve our aim, whether we understand the process or not.
Enjoy the holidays, everyone. I’ll be back soon with some thoughts on what to expect in the realm of digital health in the coming year—and we’ll return with Brainstorm Health Daily on Jan. 2.
Apple continues its quest to make smartwatches medical devices. Bloomberg reports that Apple is developing an EKG heart monitor for future smartwatches, adding to the company’s burgeoning medical device and mobile health efforts. Current Apple devices already come with heart monitors; but the inclusion of true EKG tech could have far-reaching implications, including for detecting and monitoring atrial fibrillation and other heart conditions. (Bloomberg)
Roche snatches up cancer drug maker Ignyta. Swiss pharmaceutical giant Roche is buying up some U.S. cancer-focused pharmaceutical talent for $1.7 billion: biotech Ignyta, whose cancer treatment targets a certain kind of mutation that’s present in many kinds of cancerous tumors. The drug is widely expected to win FDA approval, giving Roche access to a more-or-less certain R&D bet. (Fortune)
THE BIG PICTURE
Obamacare enrollment defies expectations with last-minute enrollment surge. The signup period for Obamacare was slashed in half this year. Despite an initially strong pace in signups, the enrollment numbers were widely expected to drop compared with last year given the constant political turmoil over the law and the Trump administration’s cuts to outreach funding. But a last-minute push in the final days of the open enrollment period, which ended December 15, pushed Healthcare.gov signups to 8.8 million, just 400,000 short of last year’s numbers. The reason? Efforts by employers, insurers, and advocates to get Americans signed up for individual health insurance plans. (Fortune)
Happy holidays and a happy New Year! It’s been a pleasure producing our first full year of Brainstorm Health Daily. Thank you for reading and all the wonderful, constructive feedback. See you in 2018!
How Tesla and Elon Musk Are Designing a New Paradigm for Drivers, by Erika Fry
Apple Poaches 3 Amazon Studios Execs, by Don Reisinger
How One Apollo 8 Photo Changed the World, by Alex Scimecca
Wall Street Giant Goldman Sachs Is About to Start Trading Bitcoin, by Bloomberg
Produced by Sy Mukherjee @the_sy_guy email@example.com
Find past coverage. Sign up for other Fortune newsletters.